10.6084/m9.figshare.9789284.v2 Yvette Lamb Yvette Lamb Topical glycopyrronium tosylate in primary axillary hyperhidrosis: a profile of its use Adis Journals 2019 Glycopyrronium tosylate primary axillary hyperhidrosis review Adis Q&A 2019-10-01 00:03:10 Online resource https://adisjournals.figshare.com/articles/online_resource/Topical_glycopyrronium_tosylate_in_primary_axillary_hyperhidrosis_a_profile_of_its_use/9789284 <p>Compliance with ethical standards </p><p><i><br></i></p><p><i>Funding</i>: The preparation of this review was not supported by any external funding.<br></p><p><br></p> <p><i>Conflicts of interest:</i> Y. N. Lamb is an employee of Adis International Ltd./Springer Nature, is responsible for the article content and declares no conflicts of interest.</p><p><br></p><p>Additional information about this Adis Drug Review can be found <b><a href="http://www.springer.com/gp/adis/products-services/adis-journals-newsletters/adis-drug-reviews">here</a></b><br></p><p><br></p><p>Abstract</p><p><br></p><p>Glycopyrronium tosylate (Qbrexza™) is available as single-use, pre-moistened cloths and has been approved in the USA for the topical treatment of primary axillary hyperhidrosis in adults and children ≥ 9 years of age. Glycopyrronium tosylate is effective in reducing patient-reported severity of disease and gravimetrically measured sweat production in this patient population; improvements have been shown to be maintained throughout long-term treatment (up to 48 weeks). Glycopyrronium tosylate is generally well tolerated, with most adverse events being mild to moderate in severity. Glycopyrronium tosylate thus provides a self-administered, non-invasive alternative to topical antiperspirant therapy and clinic-based treatments in adults with primary axillary hyperhidrosis, and is the only alternative to topical antiperspirants specifically approved in children and adolescents ≥ 9 years of age.<br></p><p><br></p><p>© Springer Nature Switzerland AG 2019<br></p>